The day at a glance · 6 sections · 3 min read
Mood · Risk-On
+68
Sentiment, −100 to +100
NYSE Healthcare Index
+2%+2%
Healthcare Market Overview
Dupilumab Global Sales
$11.9B
Big Pharma & Biotech
Amgen Stock
+3.1%+3.1%
Big Pharma & Biotech
Key driverStrong blockbuster drug performance and favorable regulatory developments support sector gains
Daily briefHealthcare· Money365.Market AI ·
Dupilumab Hits $11.9B; Amgen Blocks State Price Cap
Big Pharma advances on blockbuster sales and regulatory wins while Pfizer signals M&A intent and Thermo Fisher backs cystic fibrosis trial.
Healthcare Market Overview
Bullish01JNJ
Healthcare stocks advanced with the NYSE Healthcare Index rising 2% as the sector benefited from strong commercial performance of blockbuster drugs and favorable regulatory developments. Members of Congress have been adding positions in Johnson & Johnson ($JNJ) and UnitedHealth ($UNH), signaling confidence in healthcare policy and regulatory frameworks. The sector showed resilience amid broader market uncertainty, with S&P 500 futures edging down 0.01% on cooling labor market data.
Big Pharma & Biotech
BullishAntidiabetic Market 2026
$115.02B
Antidiabetic Market 2035
$309.84B+11.62% CAGR
01REGN
Regeneron Pharmaceuticals ($REGN) continued to drive commercial success with Dupilumab achieving record sales of $11.9 billion globally, propelled by its established market presence, new indications including COPD, and strong clinical performance across multiple conditions.
02AMGN▲ +3.10%
Amgen ($AMGN) shares jumped 3.1% after receiving a favorable court ruling that blocked a first-of-its-kind state price cap on its blockbuster drug Enbrel, providing relief on pricing pressure concerns.
03PFE
Pfizer ($PFE) signaled acquisition intent with its CEO highlighting the company's balance sheet capacity for deals, while Merck ($MRK) hit new highs and traded in a buy zone. The global antidiabetic drugs market is projected to reach $309.84 billion by 2035, expanding at an 11.62% CAGR from $115.02 billion expected in 2026, according to Healthcare Foresights research.
Clinical Trials & Manufacturing
NeutralYutrepia Q1 Sales
$130M
01TMO
Thermo Fisher Scientific ($TMO) announced a partnership with Arcturus to support the Phase III ARCT-032 cystic fibrosis trial, providing integrated manufacturing, clinical research and commercial readiness services. The collaboration positions Thermo Fisher to support advanced gene therapy development through late-stage clinical testing. LQDA's Yutrepia launch continued gaining traction with $130 million in Q1 sales, with rising prescriptions and profitability as the company expands in pulmonary arterial hypertension.
Health Insurance & Managed Care
NeutralCigna Pharmacy Forward Investment
$100M
01UNH
UnitedHealth ($UNH) attracted congressional investment interest as lawmakers positioned in health insurance providers following the Q1 earnings season. Cigna's Evernorth launched AI-powered Pharmacy Forward with a $100M investment to accelerate specialty prescriptions, reduce delays and improve efficiency in specialty pharmacy operations. The health insurance providers sector completed Q1 reporting with performance varying across the industry.
Medical Devices & Diagnostics
NeutralBoston Scientific Neuromodulation Growth
+15%+15%
01ISRG
Intuitive Surgical ($ISRG) appeared in investor discussions around market capitalization and long-term compounding opportunities in the surgical robotics sector.
02ABT
Abbott Laboratories ($ABT) was referenced in analysis of Boston Scientific's portfolio, which showed acceleration in core franchises including Neuromodulation and Interventional Oncology businesses posting organic sales growth of 15% last quarter.
03ABBV
AbbVie ($ABBV) was highlighted in research reports examining the broader healthcare sector's performance and opportunities.
Looking Ahead
NeutralAMGNPFEMRNA
01
The sector faces continued scrutiny over drug pricing policy as Amgen's court victory on state price caps sets a precedent for industry pricing dynamics. Pfizer's M&A signaling suggests potential consolidation activity ahead as the company seeks to deploy its balance sheet.
02MRNA
Moderna ($MRNA) appeared in analysis of cash-heavy stocks with warning signs, as companies with strong balance sheets face questions about growth generation and profitability consistency. Medicare negotiations and regulatory frameworks remain key watchpoints for policy-sensitive healthcare names.
Important Disclaimer — Not Investment Advice
Disclaimer: This article is provided by Money365.Market for general information and educational purposes only. It is not financial advice, a personal recommendation, or an inducement to buy, sell, or invest in any security or product. Capital is at risk and the value of investments can go down as well as up; past performance does not indicate future results. You should seek independent advice from an FCA-authorised adviser before making any financial decision.
Read the full disclaimer — 8 further points, including total-loss risk, our regulatory status and conflicts of interest
Nothing here is an offer or a solicitation to buy or sell anything, and reading it creates no advisory or fiduciary relationship between you and Money365.Market. Any decision you take is your own.
- You can lose money — including all of it. Individual companies can and do fail, and some of the assets discussed can fall to zero. Only commit money you can afford to lose, and never borrow to invest on the strength of anything you read here.
- Forecasts are opinion, not fact. Any valuation model, scenario, fair-value range, estimate or other forward-looking statement is illustrative, rests on assumptions that may prove wrong, and is never a price target, a forecast of actual outcomes, or a promise of any return.
- Published at a point in time. Figures were believed accurate on the publication or last-updated date shown above and are not maintained afterwards; we are under no obligation to update them. Market and company data comes from third-party sources and is provided without warranty of accuracy, completeness or timeliness.
- Automated content. This brief was compiled by an automated pipeline from validated news and market-data sources and passed through editorial and compliance checks. Automated content can still contain errors — verify anything you intend to rely on.
- We are not regulated. Money365.Market is not authorised or regulated by the UK Financial Conduct Authority, is not registered with the U.S. Securities and Exchange Commission or FINRA as an investment adviser or broker-dealer, and is not a tax adviser. We hold no licence to give personal financial advice and do not do so.
- Interests and independence. Money365.Market is not affiliated with, endorsed by or sponsored by any company, fund, exchange or platform mentioned, and is not paid to feature them. The author may hold positions in securities or assets discussed. The site earns revenue from advertising, subscriptions and, where labelled, affiliate links; this does not influence what we publish.
- Your jurisdiction matters. Tax treatment, contribution limits, product availability and investor protections differ by country and can change. Speak to a qualified tax professional for tax matters, and to a locally licensed adviser if you are outside the UK.
Full terms: Disclaimer · Terms of Service · Privacy Policy